Rituximab treatment for nonparaneoplastic autoimmune retinopathy

Can J Ophthalmol. 2015 Dec;50(6):e101-4. doi: 10.1016/j.jcjo.2015.08.009.

Authors

Austin Fox¹, Brett Jeffrey¹, Sarfaraz Hasni², Robert Nussenblatt³, H Nida Sen⁴

Affiliations

¹ National Eye Institute, Bethesda, Md.
² National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Md.
³ National Eye Institute, Bethesda, Md; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Md.
⁴ National Eye Institute, Bethesda, Md; National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Md. Electronic address: senh@nei.nih.gov.

PMID: 26651312
DOI: 10.1016/j.jcjo.2015.08.009

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Autoimmune Diseases / diagnosis
Autoimmune Diseases / drug therapy*
Autoimmune Diseases / physiopathology
Electroretinography
Evoked Potentials, Visual
Female
Fluorescein Angiography
Humans
Immunologic Factors / therapeutic use*
Middle Aged
Paraneoplastic Syndromes, Ocular / drug therapy
Retinal Diseases / diagnosis
Retinal Diseases / drug therapy*
Retinal Diseases / physiopathology
Rituximab / therapeutic use*
Tomography, Optical Coherence
Vision Disorders / diagnosis
Vision Disorders / drug therapy*
Vision Disorders / physiopathology
Visual Fields

Substances

Immunologic Factors
Rituximab

Grants and funding